Repligen Corporation (RGEN)

Repligen's stock price has declined approximately 19.26% over the past six months. In Q1 2026, Repligen reported EPS of $0.48, surpassing forecasts by 26.32%, and revenue reached $194 million, a 15% year-over-year increase. Following the strong Q1, Repligen raised its full-year adjusted EPS guidance to $1.97–$2.05 and reaffirmed its 2026 revenue outlook of $803M–$833M. Repligen divested its Polymem operation in France on March 30, 2026, resulting in a $13.763 million loss on the sale. In April 2026, Repligen signed a partnership agreement in China to increase its competitiveness and access to local manufacturing in the APAC region. Analysts have maintained a "Moderate Buy" consensus rating for RGEN, with a potential upside of about 37.4% from its current price.

The demand for Repligen's products and services is primarily influenced by the global demand for biologic drugs and the overall volume of therapeutic molecules manufactured. While the healthcare sector generally experiences a period of seasonal strength, Repligen's Q1 2026 earnings call indicated healthy demand across its broad portfolio and all geographies, with consumables and capital equipment showing solid growth.

Repligen Corporation is a global life sciences company focused on developing and commercializing bioprocessing technologies and systems to enhance the manufacturing of biological drugs. The company operates in the biotechnology, pharmaceutical, and laboratory equipment industries, with a focus on bioprocessing since 2012. Repligen's major product categories include Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. Filtration and Fluid Management is the largest category, accounting for 58% of 2024 revenue. Chromatography represents 19% of 2024 revenue. Process Analytics contributed 9% to 2024 revenue. Proteins makes up 12% of 2024 revenue.

Repligen is headquartered in Waltham, Massachusetts, and has a significant global presence with 22 sites. It operates manufacturing facilities and offices in the United States, Europe, and Asia Pacific. North America, Europe, and Asia Pacific contribute 44%, 37%, and 19% of its revenue, respectively. The company recently entered into a new partnership in China to advance its APAC strategy.

Repligen has a strong brand reputation as an innovation leader in bioprocessing. In December 2025, Repligen expanded its bioprocessing portfolio with the introduction of three advanced chromatography resins. The better-than-expected Q1 2026 financial results contribute positively to its reputation. The consensus "Moderate Buy" rating from analysts and positive outlook for continued growth further underscore a favorable brand perception. The company continues to work on remediating previously identified material weaknesses in internal control over financial reporting.

Repligen's ownership is predominantly held by institutional investors, who hold approximately 97.64% of the stock. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Price T Rowe Associates Inc /md/, Fmr Llc, State Street Corp, and Invesco Ltd. Individual and retail investors hold approximately 30.17% of the stock. Insider ownership ranges from 0.60% to 0.75% of total shares.